Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebif New Formulation versus placebo in relapsing-remitting multiple sclerosis
2006-003037-32Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Nov 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Rebif New Formulation with Placebo then Rebif New Formulation (2 arms). Primary endpoint: Combined unique active MRI lesions at Week 16. Started Nov 2006; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-003037-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003037-32.